Introduction
Cystic fibrosis (CF) is the most common lethal genetic disorder in Caucasians. 1, 2 The disease is characterized by the presence of thick secretions in the respiratory, gastrointestinal and reproductive tracts. 3 Much of the morbidity and mortality in CF patients result from pulmonary exacerbations. Therefore, an objective of CF gene therapy has been directed at rescuing the gene defect in the lungs. In the CF clinical trials, gene complexes (ie modified viruses or cationic liposomes carrying the gene) were instilled or nebulized into the respiratory tract. 4, 5 However, in contrast to the promising results observed in vitro and in animals, the efficiency of gene delivery in CF patients was disappointing. 6 This may be due to the fact that gene complexes delivered into the lungs of CF patients have to overcome the tenacious mucus lining the respiratory epithelium before they can enter the target cells. Indeed, Kitson et al 7 showed that when CF 'sputum' (which is defined as expectorated CF mucus) was applied on to sheep airway epithelia in vitro, gene transfer using viral vectors or cationic liposomes was significantly decreased.
CF mucus contains large amounts of proteins, DNA, mucin and phospholipids 8 and may decrease gene transfer to the underlying epithelium in different ways: (1) may sterically restrict the transport of the gene complexes to the target cells. We studied this transport barrier in our previous work. 9, 10 (2) CF mucus components may interact with the gene complexes thereby changing their structural properties. Indeed, we recently showed that CF mucus components clearly interact physicochemically with cationic lipoplexes. 8 However, besides this report, there is no additional information pertaining to this matter. In particular, it has not been determined how structural changes to the gene complexes by CF mucus constituents influence their transfection activity. Only a few papers have shown that pulmonary surfactants, which line the alveoli, decrease the gene transfer activity of cationic liposomes. [11] [12] [13] However, these authors did not elucidate in detail the underlying mechanism for this inhibition in activity.
Based on these considerations, we proposed (1) to examine whether gene transfer by lipoplexes was influenced by CF mucus components, (2) to explain the basis for the change in gene transfection activity, and (3) to determine whether lipoplexes that had been 'coated' with polyethylene glycol (pEG) were more resistant to CF mucus components than 'uncoated' lipoplexes.
Results and discussion
In this study the effect of CF mucus components on the size and zeta potential () of lipoplexes was investigated. Specifically, we examined whether structural alterations that may arise following addition of these components have an impact on gene transfection by the lipoplexes. We studied cationic, non-pegylated (DOTAP:DOPE) and pegylated (GL67) lipoplexes, respectively ( Figure 1 ). As GL67-based lipoplexes lacking DMPE-pEG 5000 , were not available, 14 we investigated cationic DOTAP:DOPE lipoplexes as a model for lipoplexes without pEG. Cationic lipoplexes based on DOTAP have also been used in a clinical trial for CF gene therapy. 15 
Characteristics of the lipoplexes in the absence of CF mucus components
The gene transfection activities, sizes and of the lipoplexes, in the absence of CF mucus components, are shown in Table 1 . Gel electrophoresis of the lipoplexes showed that all the pDNA was bound to the cationic liposomes (data not shown). The DOTAP:DOPE lipoplexes had a pronounced positive and a small size distribution, while the GL67 lipoplexes had a that was near zero, were rather large and showed a broad size distribution. The large size of the GL67 lipoplexes was most likely due to the neutral , which is probably a result of the shielding of the surface charges by polyethylene glycol chains. Additionally, the neutral may also partly be due to the fact that the +/-ratio of the lipoplexes was close to 1. The absence of extreme large (ie multi-micrometer sized) aggregates is probably due to the pEG chains which, to a certain extent, sterically stabilize the GL67 lipoplexes. This fulfills the initial purpose for inclusion of DMPEpEG 5000 , which was to minimize the precipitation of the lipoplexes when they were prepared at high concentrations.
14 Nonetheless, 4 h after preparation a small amount of the GL67 lipoplexes did precipitate.
Gene expression following transfection by DOTAP:-DOPE lipoplexes was three-fold lower compared with GL67 lipoplexes (Table 1 ). This may be partially due to a higher degree of sedimentation of the large GL67 lipo- plexes, which enhanced the lipoplex concentration at the cell surface. 16, 17 Moreover, it has also been shown by Ross and Hui 18 that the transfection activity of lipoplexes can be increased by addition of pEG to the transfection medium. According to these authors this enhancement was due to a pEG-induced lipoplex aggregation, which resulted in a higher lipoplex-cell association. Plasmid DNA alone, added to the cells in the same concentration as in the transfection experiments with the lipoplexes, did not significantly transfect the cells. To evaluate the effect of proteins, which are abundantly present in CF mucus, on gene transfection activity of the lipoplexes we used albumin (negatively charged at pH 7.4), as it is the major protein present in CF mucus. 19 The transfection activity of the cationic DOTAP:DOPE lipoplexes was significantly reduced at albumin:pDNA concentration ratios between 3.2 and 7.1 ( Figure 2a) . However, these concentration ratios are not expected to occur in vivo after administration of lipoplexes to the CF lung ( Table 2 ). Figure 2b clearly shows that between the concentration ratios 3.2 and 7.1 the DOTAP:DOPE lipoplexes lost their cationic charge ( becomes slightly negative due to binding of albumin) and formed very large aggregates (>1.5 m). This probably explains the significant decrease observed in gene expression at these concentration ratios. At higher albumin:pDNA concentration ratios smaller lipoplexes, with an extremely low of -50 mV were generated (Figure 2b ), while no free DNA was detected (data not shown). This -value is much lower than the of albumin alone (-10 ± 1 mV), which indicates (Figure 2a ). At these concentration ratios, the size and also did not change significantly (Figure 2c ), which indicates that the pEG chains probably prevented binding of albumin to the GL67 lipoplexes. At albumin:pDNA concentration ratios from 79 onwards, of the GL67 lipoplexes decreased, although the size of the lipoplexes remained unchanged ( Figure 2c ). This was probably due to sterical stabilization by pEG and electrostatic repulsion arising from the negative surface charge. Also, from concentration ratios of 40 onwards, free pDNA was present (Table 3 ). These structural alterations probably explain the decrease in gene expression at the highest albumin:pDNA concentration ratios ( Figure 2a ). However, at albumin:pDNA concentration ratios 40 and 79 gene transfer was still high (~100%) (Figure 2a ), while free pDNA was detected. At these concentration ratios, pDNA was probably 'loosely bound' to the lipoplexes, which resulted in a detachment of these loosely bound pDNA chains from the GL67 lipoplexes by the electric field during the gel electrophoresis experiments (Table 3) .
Does linear DNA influence gene expression, zeta potential and size of cationic DOTAP:DOPE lipoplexes?
One distinctive characteristic of CF mucus is the presence of high concentrations of DNA, which originates from the lysis of neutrophils, bacteria and epithelial cells. 20 This highly negatively charged DNA might interact with the cationic gene complexes, and thereby form an obstacle to CF gene therapy.
At linear DNA:pDNA concentration ratios between 1.3 and 1.6, which may occur in vivo, a significant reduction in gene expression by the DOTAP:DOPE lipoplexes was observed ( Figure 3a) . Again, as observed with albumin, at these concentration ratios was near zero and large aggregates were present (Figure 3b ), which again probably explains the decrease in gene expression. Very small (Ͻ5%) amounts of free pDNA were also present from a linear DNA:pDNA concentration ratio of 1.6 onwards (data not shown). As observed with albumin, at higher linear DNA:pDNA concentration ratios, again small DOTAP:DOPE lipoplexes with a low of about -65 mV were generated (Figure 3b ). This observation supports the suggestion that the lipoplexes became coated with a 
Are pegylated GL67 lipoplexes more resistant to interaction with linear DNA?
In contrast to DOTAP:DOPE lipoplexes, gene expression by GL67 lipoplexes was not significantly inhibited by linear DNA (Figure 3a) , although the measured of the linear DNA/GL67 lipoplex mixtures indicated a change in of the lipoplexes (Figure 3c ). However, the of linear DNA alone also showed a decrease at higher linear DNA concentrations and these -values were always lower than the measured in the corresponding linear DNA/GL67 lipoplex mixtures. Therefore, the -data in Figure 3c were most probably not the of the lipoplexes as they were influenced by the of free linear DNA. Furthermore, linear DNA did not change the size of the lipoplexes (Figure 3c ) and did not release pDNA (data not shown). 
Does mucin influence gene expression, zeta potential and size of cationic DOTAP:DOPE lipoplexes?
Mucins, which are major biopolymers in mucus, are negatively charged owing to the presence of N-acetylneuraminic acid and sulfated sugars. 21 Gene expression by DOTAP:DOPE lipoplexes was significantly decreased at all the mucin:pDNA concentration ratios studied (Figure 4a ). At a concentration ratio below 9.5, binding of mucin to the cationic lipoplexes resulted in charge neutralization and aggregation (Figure 4b ), which may explain the decrease in gene transfer activity (Figure 4a ). At higher mucin:pDNA concentration ratios, the and size equaled the and size of mucin alone (-20 ± 1 mV and 687 ± 44 nm respectively), indicating that free mucin determined the outcome of the size andmeasurements in Figure 4b . Therefore, it could not be elucidated whether aggregation of the DOTAP:DOPE lipoplexes was the cause of the low gene expression observed (Figure 4a) . Furthermore, the decrease in gene expression may not only be due to binding of mucin to the lipoplexes. Indeed, precipitation of large mucin clusters on top of the cells may have prevented interaction of the lipoplexes with the cells. Finally, gel electro-phoresis did not show the presence of free pDNA after mixing the lipoplexes with mucin (data not shown).
Are pegylated GL67 lipoplexes more resistant to interaction with mucin?
As observed in the experiments with albumin and linear DNA, at mucin:pDNA concentration ratios that may be present in vivo (Table 2) , no change in gene expression was observed with the GL67 lipoplexes ( Figure 4a ). As explained above, the steady decrease in and size of the mucin/GL67 lipoplex mixtures (Figure 4c ) was most likely due to free mucin, which, especially at higher mucin concentrations, determines the measurements. At the highest mucin:pDNA concentration ratios, a decrease in gene expression occurred (Figure 4a) , which, as suggested for the DOTAP:DOPE lipoplexes, may be attributed to large mucin clusters which precipitated on the surface of the cells.
Does Alveofact influence gene expression, zeta potential and size of cationic DOTAP:DOPE lipoplexes?
It is known that CF mucus contains phosphatidylcholine and phosphatidylglycerol. 8, 22, 23 Others have reported that Alveofact, a natural pulmonary surfactant, forms a barrier to cationic lipid-mediated gene transfer. [11] [12] [13] We examined whether this also held true for our lipoplexes.
At Alveofact:pDNA concentration ratios expected to occur in vivo (Table 2) , no decrease in gene transfection by the DOTAP:DOPE lipoplexes was observed ( Figure  5a) . Instead, at concentration ratios between 0.16 and 1.8 a significant increase was observed. Also, Duncan et al 11 have reported an increase in gene expression in the presence of Alveofact. They attributed this to binding of surfactant protein B and C, present in small amounts in Alveofact, to the surface of the cationic lipoplexes, which enhances their binding to epithelial cells. Another explanation could be that the phospholipids in Alveofact enhanced gene transfer by increasing the cell permeability. 24 Figure 5a shows that from Alveofact:pDNA concentration ratios of 16 onwards, gene expression significantly decreased (Figure 5a ). As in that region became close to zero and aggregation of the lipoplexes occurred (Figure 5b) , it is clear that the structural changes of the DOTAP:DOPE lipoplexes due to binding of surfactants are at the origin of the lowered gene expression. We also observed that at the two highest concentration ratios Alveofact resulted in the release of a small amount of pDNA from the DOTAP:DOPE lipoplexes (data not shown).
Are pegylated GL67 lipoplexes more resistant to interaction with Alveofact? Figure 5a demonstrates that Alveofact did not inhibit the gene transfection activity of GL67 lipoplexes at Alveofact:pDNA concentration ratios that are present in vivo. This was expected as Figure 5c shows that in this region no change, either in size or in was observed However, from a concentration ratio of 24 onwards, Alveofact decreased to about -10 mV (Figure 5c ). The of Alveofact alone equalled -15 ± 1 mV, while particles with a size of 406 ± 13 nm were present. These negatively charged particles were probably liposomes. Therefore, the decrease in of the lipoplexes after mixing with Alveofact was probably due to increasing amounts of 'Alveofact' liposomes present upon increasing the AlveoGene Therapy fact:pDNA concentration ratio. Additionally, lipoplexes mixed with the two highest Alveofact concentrations resulted in the liberation of about 15% of pDNA (data not shown). This indicates that Alveofact did interact with the GL67 lipoplexes and probably also explains the decrease in gene expression, although not significant, at the two highest Alveofact:pDNA concentration ratios.
Does the behavior of lipoplexes in the presence of individual CF mucus components predict their behavior in CF sputum?
To examine whether the phenomena observed upon mixing individual CF mucus components with lipoplexes may predict their behavior in native CF sputum, we incubated lipoplexes with CF sputa collected from CF patients. As there are no methods to measure particle size and of lipoplexes in media like sputum, we were only able to evaluate the release of pDNA from the lipoplexes upon exposure to sputum. We compared these results with the outcome on the release of pDNA as observed upon mixing the lipoplexes with individual CF mucus components.
From the dissociation experiments with DOTAP:DOPE Gene Therapy lipoplexes by CF mucus components, we concluded that linear DNA above a linear DNA:pDNA concentration ratio of 1.6 was able to release small amounts of pDNA from the lipoplexes. In a previous study we experimentally showed that lipoplexes mixed with CF sputa indeed started to dissociate when the linear DNA:pDNA concentration ratio in the mixtures was above 1.6.
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From the dissociation experiments on the GL67 lipoplexes by CF mucus components we showed that only albumin was able to disassemble these lipoplexes (although artificially) at concentration ratios that exist in vivo (Tables 2 and 3 ). Indeed, dissociation was observed from an albumin:pDNA concentration ratio of 40 onwards. To see whether this holds true for CF sputum, we mixed the GL67 lipoplexes with five different CF sputa (a, b, c, d and e in Table 4 ). For each sputum sample we calculated, based on its protein concentration and the assumption that all the protein material is albumin, the albumin:pDNA concentration ratios ( Table 4) . As CF sputum harbors DNase activity (due to the presence of endogenous or administrated DNase), that would degrade pDNA liberated from the lipoplexes, we also incubated free pDNA with the sputa as a control. Figure  6a shows that after gel electrophoresis of the sputum/lipoplex (lanes a1, b1, c1, d1 and e1) and sputum/free pDNA (lanes a2, b2, c2, d2 and e2) mixtures, a smear of DNA (which may contain both linear and pDNA) was observed. Therefore, to determine whether pDNA was released from the cationic liposomes the gels were blotted. Figure 6b shows that the pDNA in the controls (lanes a2, b2, c2, d2 and e2) again resulted in a smear. This smear, most likely a result of the nuclease activity in the sputum, had not migrated as far as the pDNA bands in lane 4, which contains pDNA without sputum. This was probably attributed to the higher viscosity of the sputum/pDNA mixtures. Lanes a1, b1, c1 and d1 of Figure 6b show that the GL67 lipoplexes in the CF sputa did not dissociate. This was also expected as the albumin:pDNA concentration ratios in these mixtures were lower than 40 (Table 4) . On the other hand, sputum sample (e) did release a very small amount of pDNA (figure 6b). Based on the albumin:pDNA concentration ratio in this mixture (ie 51) and the amount of free pDNA observed upon mixing GL67 lipoplexes with albumin at a comparable concentration ratio (Table 3) , we would expect a higher amount of released pDNA. However, binding of albumin to mucin via hydrophobic interactions has been reported. 25 This may lower the concentration of 'free' albumin in the CF sputum, which can interact with the lipoplexes.
In conclusion, we report here studies on the biophys- Table 4 Protein concentration in the CF sputa used in the release experiments ( Figure 6 ) and the calculated albumin:pDNA concentration ratios (n = 3, n = 1 a ) ical stability and the transfection activity of lipoplexes upon exposure to CF mucus components. As shown, alterations of lipoplexes by CF mucus may occur in different ways. First, CF mucus components may release pDNA from the lipoplexes. Secondly, binding of negatively charged CF mucus components to the lipoplexes might change their surface charge resulting in the formation of aggregates. Previously, we showed that the transport of lipoplexes through CF mucus is highly dependent on their size and becomes almost completely blocked at sizes larger than 500 nm. Consequently, aggregation of the lipoplexes induced by CF mucus may drastically lower their gene expression through both a decreased mobility in CF mucus and a decreased uptake of the aggregated lipoplexes by the cells. Albumin, linear DNA and mucin significantly decreased gene expression of the cationic DOTAP:DOPE lipoplexes when we mixed these components with the lipoplexes at concentration ratios that may occur in vivo after administration of lipoplexes to the CF lung. This lowered gene expression was due to aggregation of the lipoplexes by these CF mucus components. However, at concentration ratios expected to occur in vivo, none of the CF mucus components studied altered the gene expression by the pegylated GL67 lipoplexes. We experimentally showed that at these concentration ratios the biophysical properties of these lipoplexes indeed did not change upon exposure to the CF mucus components. However, at high albumin:pDNA and Alveofact:pDNA concentration ratios, which are not expected to exist in vivo, gene transfection by the GL67 lipoplexes significantly decreased. It was shown that this was due to a partial release of pDNA from the lipoplexes. It seems that at high concentrations, in contrast to linear DNA and mucin molecules, albumin and phospholipids (which have lower molecular weights) can penetrate between the pEG chains on the surface of GL67 lipoplexes and compete with pDNA for binding to the cationic lipids.
The dissociation of DOTAP:DOPE lipoplexes by linear DNA and the dissociation of GL67 lipoplexes by albumin was confirmed in experiments using native CF sputa. As expected from the release of pDNA by single CF mucus components, no release of pDNA from the DOTAP:DOPE lipoplexes occurred when the linear DNA:pDNA concentration ratio in the lipoplex/sputa mixtures was below 1.6 and no release of pDNA from the GL67 lipoplexes occurred when the albumin:pDNA concentration ratio in the lipoplex/sputa mixtures was below 40.
Our data indicate that shielding of the surface charge of lipoplexes by pEG chains diminishes their interactions with CF mucus components. Consequently, compared with non-pegylated DOTAP/DOPE lipoplexes, gene transfection by the pegylated GL67 lipoplexes was less influenced by CF mucus components. Therefore, it seems that the higher gene transfer activity of the GL67 lipoplexes in vivo, besides the good transfection properties of the GL67 lipid, is also due to the fact that pEG chains protect the lipoplexes against interaction with CF mucus components. However, as the two compared lipoplexes also differed in lipid composition, it is also possible that the DOTAP:DOPE lipoplexes were inherently more likely to interact with the sputum components than the GL67 lipoplexes. Finally, we were also able to show that the changes in the gene transfection activity of the lipoplexes could well be correlated with, and explained by structural alterations of the lipoplexes. Consequently, the experimental setup described in this paper will be helpful in evaluating to what extent new gene carriers may be suitable for use in CF gene therapy.
Materials and methods

Reagents
Albumin (from bovine serum), linear double-stranded DNA (from salmon testes, indicated as linear DNA in this study), mucin (from bovine submaxillary glands), 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (Hepes) and bovine intestinal alkaline phosphatase were purchased from Sigma (Bornem, Belgium). Alveofact, a dispersion of pulmonary surfactants from bovine lung lavage was a gift from Boehringer Ingelheim (Brussels, Belgium). It contains 54 mg surfactants/ml of which 93% are lipids. The most abundant phospholipids are phosphatidylcholine (82% of total lipid content) and phosphatidylglycerol (11.5% of total lipid content). Dioleoylglycerophosphoethanolamine (DOPE) and 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Dried lipid films of GL67:DOPE:DMPE-pEG 5000 (1:2:0.05 molair ratio) were from Genzyme Corporation (Framingham, MA, USA). The GL67 lipid contains three protonable nitrogen atoms. DMPE-pEG 5000 is dimyristoylphosphatidylethanolamine (DMPE) that is covalently coupled to a polyethylene glycol (pEG) having a molecular weight of 5000 g/mol. The Maxi Prep kit was obtained from Qiagen (Leusden, The Netherlands). TOTO-1 was from Molecular Probes (Leiden, The Netherlands). Electrophoresis grade agarose, Dulbecco's phosphate-buffered saline (PBS), Dulbecco's modified Eagle's medium (DMEM), 
Preparation of pDNA
The pDNA consisted of 5803 base pairs (bp) and encodes the reporter gene secretory alkaline phosphatase (SEAP) under the control of the simian virus 40 promotor. The pDNA was amplified, purified and dissolved in Hepes buffer at a concentration of 1.0 g/l as previously described. 8 
Preparation of cationic liposomes
The GL67:DOPE:DMPE-PEG 5000 (1:2:0.05; molar ratios) liposomes were prepared as follows. Dried lipid films, containing 4 mol of GL67, 8 mol DOPE and 0.2 mol DMPE-PEG 5000 were hydrated for 10 min at 4°C with 3.60 ml sterile, distilled water and then vortexed for 2 min. The size and of these liposomes (in water) equalled 340 ± 15 nm and +53 ± 1 mV, respectively. Cationic liposomes containing DOTAP and DOPE (1:1 molar ratios) were prepared in Hepes buffer at a concentration of 5 mm DOTAP as previously described. 8 The size and of these liposomes (in Hepes buffer) equalled 124 ± 9 nm and +50 ± 2 mV, respectively.
Preparation of lipoplexes
For the preparation of the DOTAP:DOPE lipoplexes (Figure 1 ), we first diluted plasmid DNA in Hepes buffer to a concentration of 0.41 mg/ml. Subsequently, the diluted pDNA was added to an equal volume of cationic liposomes (5 mm DOTAP) resulting in a final +/-charge ratio of 4. Immediately after the addition of pDNA to the cationic liposomes, Hepes buffer was added until the final concentration of pDNA was 0.126 mg/ml. This mixture was then vortexed and incubated at room temperature for 30 min.
For the preparation of the GL67 lipoplexes ( Figure 1 ) the pDNA and the GL67:DOPE:DMPE-PEG 5000 (1:2:0.05 molar ratio) liposomes were diluted in sterile, distilled water to 0.252 g/l pDNA and 0.573 mm GL67, respectively. Equal volumes of diluted liposomes and pDNA were incubated at 35°C for 3 min. Consequently, the liposomes were added to the pDNA without vortexing and the complexes were allowed to form for at least 30 min. The GL67:pDNA molar ratio in these lipoplexes was 0.75:1 (molar concentration of pDNA based on an average nucleotide molecular mass of 330 g/mol) and the final pDNA concentration in the lipoplexes was 0.126 g/l. The calculation of the +/-charge ratio of the GL67 lipoplexes was difficult as the pKas of the nitrogen atoms (which are necessary to calculate the amounts of positive charges) are unknown. Compared with other types of lipoplexes, the GL67-based lipoplexes described above were most effective after aerosol delivery into the lungs of mice, 14 and consequently, were used in a clinical trial by Alton et al. 4 
Mixing lipoplexes with CF mucus components
To study the interactions between the lipoplexes and CF mucus components as they occur in the lungs of CF patients, the lipoplexes were mixed with CF mucus components in concentration ratios which are expected to occur in vivo. For a particular CF mucus component this concentration ratio, which was called 'in vivo concentration ratio', was calculated as follows:
in vivo concentration ratio = average concentration of the component in the mucus after nebulization (mg/ml)/concentration of pDNA (complexed to cationic liposomes) expected in the mucus after nebulization (mg/ml)
The average concentration of the CF mucus components has been previously determined. 8 The concentration of pDNA expected in the mucus was obtained by assuming that 35% of the lipoplex aerosol administered to the lungs in the clinical trial by Alton and co-workers 4 reached the mucus covered airways. The total administered aerosol volume in this study was 16 ml and the pDNA concentration in the aerosol was 2.1 mg/ml. A main weakness of this approach is that for the calculations of the in vivo concentration ratio many assumptions have been made. Moreover, the concentrations of the CF mucus components differ from patient to patient. 8 We therefore defined a range in which these 'in vivo concentration ratios' may vary (Table 4) .
Transfection assay
A constant volume of lipoplexes (50 l) was mixed with increasing concentrations of CF mucus components (albumin, linear DNA, mucin and Alveofact) which were dissolved/suspended in 50 l sputum buffer. After 40 min of incubation, the effect of the CF mucus components on gene expression by the lipoplexes was evaluated using Cos1 cells. These cells (16 000 cells per well) were grown at 37°C under 5% CO 2 for 48 h in 24-well plates using DMEM supplemented with penicillin and streptomycin sulfate (respectively 50 IU/ml and 50 g/ml) and 10% fetal calf serum as growth medium. Just before transfection, cells were washed twice with sterile HBSS. Subsequently, 5 l (for DOTAP:DOPE lipoplexes) or 25 l (for GL67 lipoplexes) of the CF mucus component/lipoplex mixtures was added to, 495 l and 475 l of sputum buffer, respectively supplemented with 1.7% glucose (to make the solution isotonic) and applied to the cells. This resulted in 0.32 g and 1.58 g pDNA per well, respectively, for DOTAP:DOPE and GL67 lipoplexes. After 4 h the lipoplexes were removed, cells were rinsed twice with sterile PBS and 500 l growth medium was added. Two days later, SEAP activity was determined in the medium using 4-methylumbelliferyl phosphate 26 and bovine intestinal alkaline phosphatase as a standard. To compare gene transfection by the two lipoplexes in the absence of CF mucus components (Table 1) , we applied the same amount (0.32 g) of pDNA per well on to the cells. To minimize the effects of differing cell numbers and cell growth per well, the amount of SEAP activity was normalized by dividing the SEAP activity by the total protein content in the corresponding well. Protein content was measured using the Bradford assay following addition of lysis buffer (0.1% Triton X-100 in PBS). 27 
Determination of particle size and zeta potential
The influence of the CF mucus components on the size and of the lipoplexes were measured by dynamic light scattering (Autosizer 4700; Malvern, Worcestershire, UK) and particle electrophoresis (Zetasizer 2000; Malvern), respectively. A constant volume of lipoplexes (50 l) was mixed with 50 l sputum buffer which contained increasing concentrations of mucus components. This resulted in mucus component:pDNA concentration ratios similar to the ones used in the transfection experiments. After 40 min these mixtures were diluted with sputum buffer to a final volume of 2.0 ml (the minimal volume needed for the measurements) and the z-average diameter and were measured. We also determined the size and of the CF mucus components in the absence of lipoplexes. This was done by mixing 50 l sputum buffer, instead of lipoplexes, with 50 l sputum buffer containing increasing concentrations of mucus components. Subsequently, the size and was measured as described above.
Determination of the amount of pDNA dissociated from the lipoplexes Lipoplexes (25 l), which contained pDNA labeled with TOTO-1 at a dye to bp ratio of 1:40, were incubated at room temperature with increasing concentrations of a mucus component dissolved/suspended in 25 l sputum buffer. The resulting mucus component:pDNA concentration ratios were similar to those used in the transection experiments. After 40 min we mixed 6 l of loading buffer (50% wt:vol sucrose in sputum buffer) with the mucus component/lipoplex mixtures and loaded 20 l of the resulting mixtures into the wells of a 1% (wt:vol) low melting point agarose gel prepared in electrophoresis buffer. Subsequently, the gel was electrophoresed at 100 V for 1 h. After electrophoresis the pDNA bands were excised from the gel and the pieces of agarose gel were dissolved by incubation at 65°C for 15 min. The fluorescence ( excitation = 513 nm and emission = 533 nm) was measured at 30°C. The percentage of free pDNA was obtained by comparing the measured fluorescence to that of a standard curve generated by running free pDNA on a gel. This pDNA was stained by TOTO-1 at a dye to bp ratio of 1:40.
The release of pDNA from the GL67 lipoplexes by CF sputum was studied by gel electrophoresis followed by Southern blotting as previously described. 8 
Cystic fibrosis sputa
Approval for the collection of CF sputa was obtained from the ethics committee of the University Hospital of Ghent. The sputum was expectorated spontaneously by CF patients during chest physiotherapy sessions in the CF center of De Haan (Zeepreventorium). After a twofold dilution of the sputa with 6 mm DTT in sputum buffer, the total protein concentration was measured. 28 
Data analysis
The experimental results in this paper are expressed as means ± standard error. Unless otherwise stated, all the data were analyzed for statistical significance using the Student's t test. A value of P Ͻ 0.01 was considered statistically significant.
